E. Campo and S. Rule, Mantle cell lymphoma: evolving management strategies, Blood, vol.125, issue.1, pp.48-55, 2015.

P. Jares, D. Colomer, and E. Campo, Molecular pathogenesis of mantle cell lymphoma, J Clin Invest, vol.122, issue.10, pp.3416-3423, 2012.

B. Meissner, R. Kridel, and R. S. Lim, The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, issue.16, pp.3161-3164, 2013.

R. Rahal, M. Frick, and R. Romero, Pharmacological and genomic profiling identifies NF-kB-targeted treatment strategies for mantle cell lymphoma, Nat Med, vol.20, issue.1, pp.87-92, 2014.

S. Beà, R. Valdés-mas, and A. Navarro, Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proc Natl Acad Sci, vol.110, issue.45, pp.18250-18255, 2013.

J. A. Burger and J. G. Gribben, The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies, Semin Cancer Biol, vol.24, pp.71-81, 2014.

P. Amé-thomas and K. Tarte, The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity, Semin Cancer Biol, vol.24, pp.23-32, 2014.

J. A. Burger and R. J. Ford, The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies, Semin Cancer Biol, vol.21, issue.5, pp.308-312, 2011.

B. Y. Chang, M. Francesco, D. Rooij, and M. F. , Egress of CD19(1)CD5(1) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients, Blood, vol.122, issue.14, pp.2412-2424, 2013.

M. L. Wang, S. Rule, and P. Martin, Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, vol.369, issue.6, pp.507-516, 2013.

D. Chiron, C. Dousset, and C. Brosseau, Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, issue.11, pp.8750-8759, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02534385

M. Furtado, M. L. Wang, B. Munneke, J. Mcgreivy, D. M. Beaupre et al., Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma, Br J Haematol, vol.170, issue.1, pp.131-134, 2015.

L. V. Pham, M. T. Vang, and A. T. Tamayo, Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease, Leuk Lymphoma, vol.56, issue.1, pp.186-193, 2015.

T. Lwin, J. Lin, and Y. S. Choi, Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a, Blood, vol.116, issue.24, pp.5228-5236, 2010.

A. V. Kurtova, A. T. Tamayo, R. J. Ford, and J. A. Burger, Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting, Blood, vol.113, pp.4604-4613, 2009.

T. Lwin, L. A. Hazlehurst, and S. Dessureault, Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas, Blood, vol.110, issue.5, pp.1631-1638, 2007.

Z. Jin, N. Teramoto, and K. Hayashi, CD40 ligand stimulation inhibits the proliferation of mantle cell lymphoma lines, Anticancer Res, vol.24, issue.2B, pp.691-697, 2004.

D. J. Medina, L. Goodell, J. Glod, C. Gélinas, A. B. Rabson et al., Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of Bcell activating factor and activation of the canonical and non-canonical nuclear factor kB pathways, Haematologica, vol.97, issue.8, pp.1255-1263, 2012.

R. Castillo, J. Mascarenhas, W. Telford, A. Chadburn, S. M. Friedman et al., Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4, Leukemia, vol.14, issue.2, pp.292-298, 2000.

N. S. Andersen, J. K. Larsen, and J. Christiansen, Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures, Blood, vol.96, issue.6, pp.2219-2225, 2000.

E. V. Planken, N. H. Dijkstra, R. Willemze, and J. C. Kluin-nelemans, Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the 'CD40 system', Leukemia, vol.10, issue.3, pp.488-493, 1996.

A. Geffroy-luseau, D. Chiron, G. Descamps, G. Jégo, M. Amiot et al., TLR9 ligand induces the generation of CD201 plasmablasts and plasma cells from CD271 memory B-cells, Front Immunol, vol.2, p.83, 2011.

C. Arpin, J. Déchanet, and C. Van-kooten, Generation of memory B cells and plasma cells in vitro, Science, vol.268, issue.5211, pp.720-722, 1995.
URL : https://hal.archives-ouvertes.fr/hal-02474293

M. A. Brennan, A. Renaud, and A. L. Gamblin, 3D cell culture and osteogenic differentiation of human bone marrow stromal cells plated onto jetsprayed or electrospun micro-fiber scaffolds, Biomed Mater, vol.10, issue.4, p.45019, 2015.

S. Maïga, C. Brosseau, and G. Descamps, A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines, Cytometry A, vol.87, issue.4, pp.285-288, 2015.

C. Vignon, C. Debeissat, and M. T. Georget, Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot, PLoS One, vol.8, issue.7, p.68425, 2013.

G. W. Foight, J. A. Ryan, S. V. Gullá, A. Letai, and A. E. Keating, Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells, ACS Chem Biol, vol.9, issue.9, pp.1962-1968, 2014.

S. Dutta, J. Ryan, T. S. Chen, C. Kougentakis, A. Letai et al., Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL

, J Mol Biol, vol.427, pp.1241-1253, 2015.

F. Baran-marszak, M. Boukhiar, and S. Harel, Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma, Haematologica, 2010.

L. Zhang, J. Yang, and J. Qian, Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells, Blood, vol.120, issue.18, pp.3783-3792, 2012.

D. Vishwamitra, P. Shi, and D. Wilson, Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma, Haematologica, vol.96, issue.6, pp.871-880, 2011.

M. Guidoboni, P. Zancai, and R. Cariati, Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma, Cancer Res, vol.65, issue.2, pp.587-595, 2005.

J. Dal-col, P. Zancai, and L. Terrin, Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma, Blood, vol.111, issue.10, pp.5142-5151, 2008.

D. M. Dorfman and G. S. Pinkus, Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23, Mod Pathol, 1994.

C. M. Annunziata, R. E. Davis, and Y. Demchenko, Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma, Cancer Cell, vol.12, issue.2, pp.115-130, 2007.

C. Dousset, S. Maïga, and P. Gomez-bougie, BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01353369

, Br J Haematol

M. Vogler, H. A. Hamali, and X. M. Sun, BCL2/BCL-X (L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation, Blood, vol.117, issue.26, pp.7145-7154, 2011.

F. Habens, A. S. Lapham, and C. L. Dallman, Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes, Oncogene, vol.26, issue.13, pp.1910-1919, 2007.

L. V. Pham, A. T. Tamayo, L. C. Yoshimura, P. Lo, and R. J. Ford, Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis, J Immunol, vol.171, issue.1, pp.88-95, 2003.

A. R. Jazirehi, S. Huerta-yepez, G. Cheng, and B. Bonavida, Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-kappaB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis, Cancer Res, vol.65, issue.1, pp.264-276, 2005.

T. Illidge, C. Klein, L. H. Sehn, A. Davies, G. Salles et al., Obinutuzumab in hematologic malignancies: lessons learned to date, Cancer Treat Rev, vol.41, issue.9, pp.784-792, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01962569

D. Chiron, D. Liberto, M. Martin, and P. , Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer Discov, vol.4, issue.9, pp.1022-1035, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02490276

N. S. Saba, D. Liu, and S. E. Herman, Pathogenic role of B-cell receptor signaling and canonical NF-kB activation in mantle cell lymphoma, Blood, vol.128, issue.1, pp.82-92, 2016.

L. Nygren, A. M. Wasik, and S. Baumgartner-wennerholm, T-cell levels are prognostic in mantle cell lymphoma, Clin Cancer Res, vol.20, issue.23, pp.6096-6104, 2014.

S. Iyengar, L. Ariza-mcnaughton, and A. Clear, Characteristics of human primary mantle cell lymphoma engraftment in NSG mice, Br J Haematol, vol.173, issue.1, pp.165-169, 2016.

M. S. Davids, J. Deng, and A. Wiestner, Decreased mitochondrial apoptotic priming underlies stromamediated treatment resistance in chronic lymphocytic leukemia, Blood, vol.120, issue.17, pp.3501-3509, 2012.

M. Vogler, M. Butterworth, and A. Majid, Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia, Blood, vol.113, issue.18, pp.4403-4413, 2009.

T. Robak, H. Huang, and J. Jin,

, Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma, LYM-3002 Investigators, vol.372, pp.944-953, 2015.

R. Thijssen, E. Slinger, and K. Weller, Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors, Haematologica, vol.100, issue.8, pp.302-306, 2015.

D. A. Heinrich, M. Weinkauf, and G. Hutter, Differential regulation patterns of the anti-CD20

E. Mössner, P. Brünker, and S. Moser, Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity, Blood, vol.115, issue.22, pp.4393-4402, 2010.

F. A. Morschhauser, G. Cartron, and C. Thieblemont, Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study, J Clin Oncol, vol.31, issue.23, pp.2912-2919, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01704593

L. H. Sehn, N. Chua, and J. Mayer, Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial, Lancet Oncol, vol.17, issue.8, pp.1081-1093, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800013

D. Chiron, P. Martin, D. Liberto, and M. , Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kd inhibition through PIK3IP1, Cell Cycle, vol.12, issue.12, pp.1892-1900, 2013.

, online October, vol.3, pp.2808-2818, 2016.

M. Steven-le-gouill, C. Amiot, and . Pellat-deceunynck,

A. Moreau, J. Esbelin, V. Trichet, S. Chen-kiang, P. Moreau et al., Sophie Maiga, expansion of mantle cell lymphoma Rational targeted therapies to overcome microenvironment-dependent

, Information about subscriptions and ASH membership may be found online at: Copyright 2011 by The, Lymphoid Neoplasia Articles on similar topics can be found in the following Blood collections, 20036.

, Blood